NeuroOne Medical Technologies Corporation (NMTC)
NASDAQ: NMTC · Real-Time Price · USD
0.9272
-0.0426 (-4.39%)
At close: Oct 30, 2026, 4:00 PM EDT
0.9272
0.00 (0.00%)
After-hours: Oct 30, 2026, 4:00 PM EDT
NMTC Revenue
NeuroOne Medical Technologies had revenue of $1.97M in the quarter ending June 30, 2026, with 16.34% growth. This brings the company's total for the last twelve months to $9.47M, up 42.84% year-over-year. In the fiscal year ending September 30, 2025, NeuroOne Medical Technologies had annual revenue of $12.10M with 250.35% growth. That makes NeuroOne Medical Technologies the 36,306th largest company in the world by revenue and 4,774th in the United States.
Revenue (ttm)
$9.47M
Revenue Growth
+42.84%
P/S Ratio
0.71
Revenue / Employee
$692,706
Employees
18
Market Cap
8.44M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 12.10M | 8.64M | 250.35% |
| Sep 30, 2024 | 3.45M | 45.37K | 1.33% |
| Sep 30, 2023 | 3.41M | 1.29M | 60.73% |
| Sep 30, 2022 | 2.12M | 1.88M | 772.60% |
| Sep 30, 2021 | 242.96K | -1.68M | -87.39% |
| Sep 30, 2020 | 1.93M | - | - |
| Sep 30, 2019 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 773.00 | -476.00 | -38.11% |
| Dec 31, 2013 | 1.25K | 328.00 | 35.61% |
| Dec 31, 2012 | 921.00 | -4.48K | -82.94% |
| Dec 31, 2011 | 5.40K | 4.23K | 362.55% |
| Dec 31, 2010 | 1.17K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| IRIDEX | 51.57M |
| Trinity Biotech | 43.79M |
| Baird Medical Investment Holdings | 24.49M |
| Biomerica | 4.34M |
| Intelligent Bio Solutions | 4.22M |
| IceCure Medical | 3.95M |
| Axonex AI Group | 2.29M |
| Sintx Technologies | 1.33M |
NMTC News
- 1 day ago - NeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation System - GlobeNewsWire
- 3 days ago - NeuroOne Featured in New York Post on OneRF® Patient's Remarkable Journey to Overcome Debilitating Facial Pain - GlobeNewsWire
- 8 days ago - NeuroOne Medical secures first pharmaceutical purchase order for StereoCED - TheFly
- 8 days ago - NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program - GlobeNewsWire
- 22 days ago - NeuroOne Medical joins Dartmouth team on $1M NIH neurotransmitter sensing grant - TheFly
- 22 days ago - NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology - GlobeNewsWire
- 25 days ago - NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order - GlobeNewsWire
- 6 weeks ago - NeuroOne Medical enters OneRF Trigeminal Nerve Ablation System distribution pact - TheFly